Across TCGA pan-cancer cohorts, KCNIP3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KCNIP3 data layer compared with 21 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher KCNIP3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KCNIP3 expression acts as an unfavorable survival marker.
SKCM, UCEC, and LUSC are the cancer types where KCNIP3 Mutation most reproducibly stratifies survival.